- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
Isradipine is a calcium channel blocker used to treat hypertension and angina. It is a dihydropyridine-type calcium channel blocker, which works by blocking the influx of calcium into the cells of the heart and blood vessels, resulting in relaxation of the vessels and a decrease in blood pressure. Isradipine is also used to treat Raynaud's phenomenon, a condition in which the fingers and toes become cold and numb due to reduced blood flow.
Isradipine is available in both oral and intravenous formulations. It is typically prescribed as a once-daily dose, although some patients may require higher doses. Common side effects of isradipine include headache, dizziness, nausea, and fatigue.
The isradipine market is a subset of the larger cardiovascular drugs market. It is a competitive market, with several companies offering isradipine products. Some of the companies in the isradipine market include Pfizer, Merck, Novartis, and Sanofi. Show Less Read more